Literature DB >> 26270443

Diagnosis of EML4-ALK Translocation With FISH, Immunohistochemistry, and Real-time Polymerase Chain Reaction in Patients With Non-Small Cell Lung Cancer.

Graciela Cruz-Rico1, Alejandro Avilés-Salas2, Manuel Segura-González3, Ana María Espinosa-García4, Laura Alejandra Ramírez-Tirado1, Vicente Morales-Oyarvide3, Carlos Rojas-Marín2, Andrés-Felipe Cardona5, Oscar Arrieta1,3.   

Abstract

OBJECTIVE: To assess anaplastic lymphoma kinase (ALK) rearrangement detection with immunohistochemistry (IHC) and real-time polymerase chain reaction (RT-qPCR) in comparison with fluorescence in situ hybridization (FISH).
METHODS: Tumor tissue samples from 230 patients with advanced non-small cell lung cancer (NSCLC) were analyzed by FISH to detect ALK rearrangements. Additional IHC tests using 5A4 clone and RT-qPCR (variants 1 to 5) were performed in 63 and 48 patients, respectively.
RESULTS: Thirteen percent of FISH tests were not evaluable. From the remaining tests (n=200), 18 (9.0%) were ALK positive (ALK). ALK patients were significantly younger at the time of diagnosis (below 55 y, 14.3% vs. 5.5%, P=0.035), were light smokers (tobacco index <10, 12.6% vs. 4.1%, P=0.049), and presented adenocarcinoma with a mucinous component (30.8 vs. 8.0%, P=0.007). When comparing FISH with IHC using a cutoff of 1+ or 2+, and only 2+ staining intensity, the sensitivity, specificity, negative predictive value, and positive predictive value were as follows: 83.3%, 100.0%, 93.75%, and 100.0%; and 55.6%, 100.0%, 84.9%, and 100.0%, respectively. For RT-qPCR, these results were 55.6, 100, 90.7, and 100.0%, respectively.
CONCLUSIONS: Our results suggest that RT-qPCR is an inadequate initial test for detecting ALK-positive lung cancer. IHC is highly useful as an initial screening test for ALK rearrangement detection in NSCLC. These results contribute to the medical literature on the establishment of IHC as a standard diagnostic test for ALK rearrangements in NSCLC.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 26270443     DOI: 10.1097/COC.0000000000000213

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  8 in total

1.  Significance and evaluation of anaplastic lymphoma kinase by immunohistochemistry in non-small cell lung cancer.

Authors:  Shuting Ding; Nan Liu; Huanyu Zhao; Guiyang Jiang; Xiupeng Zhang; Enhua Wang
Journal:  Tumour Biol       Date:  2016-02-17

Review 2.  Lung cancer mutations and use of targeted agents in Hispanics.

Authors:  W Douglas Cress; Alberto Chiappori; Pedro Santiago; Teresita Muñoz-Antonia
Journal:  Rev Recent Clin Trials       Date:  2014

Review 3.  Molecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics-Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-Cancer.

Authors:  Till Plönes; Walburga Engel-Riedel; Erich Stoelben; Christina Limmroth; Oliver Schildgen; Verena Schildgen
Journal:  J Pers Med       Date:  2016-01-15

Review 4.  Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer.

Authors:  Savvas Papageorgiou; Sarah L Pashley; Laura O'Regan; Sam Khan; Richard Bayliss; Andrew M Fry
Journal:  Cancers (Basel)       Date:  2022-07-15       Impact factor: 6.575

5.  Experimentally Deduced Criteria for Detection of Clinically Relevant Fusion 3' Oncogenes from FFPE Bulk RNA Sequencing Data.

Authors:  Elizaveta Rabushko; Maxim Sorokin; Maria Suntsova; Alexander P Seryakov; Denis V Kuzmin; Elena Poddubskaya; Anton A Buzdin
Journal:  Biomedicines       Date:  2022-08-02

6.  The correlation between crizotinib efficacy and molecular heterogeneity by next-generation sequencing in non-small cell lung cancer.

Authors:  Tangfeng Lv; Qian Zou; Zhengbo Song; Hongbing Liu; Qiming Wang; Yong Song
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

7.  5'/ 3' imbalance strategy to detect ALK fusion genes in circulating tumor RNA from patients with non-small cell lung cancer.

Authors:  Yongqing Tong; Zhijun Zhao; Bei Liu; Anyu Bao; Hongyun Zheng; Jian Gu; Mary McGrath; Ying Xia; Bihua Tan; Chunhua Song; Yan Li
Journal:  J Exp Clin Cancer Res       Date:  2018-03-27

8.  Clinical evaluation of the effectiveness of fusion-induced asymmetric transcription assay-based reverse transcription droplet digital PCR for ALK detection in formalin-fixed paraffin-embedded samples from lung cancer.

Authors:  Yuanyuan Liu; Shafei Wu; Xiaohua Shi; Linping Lu; Lingxiang Zhu; Yong Guo; Li Zhang; Xuan Zeng
Journal:  Thorac Cancer       Date:  2020-06-16       Impact factor: 3.500

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.